TNFSF11 and lung carcinoma: The efficacy of the anti‐RANKL/PD‐1 BsAb was next compared with the combination treatment with anti‐RANKL and anti‐PD‐1 antibodies in WT mice bearing s.c. CT26 colon or 3LL lung carcinoma tumors.